243 related articles for article (PubMed ID: 29376856)
21. α7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both?
Hernandez CM; Dineley KT
Curr Drug Targets; 2012 May; 13(5):613-22. PubMed ID: 22300028
[TBL] [Abstract][Full Text] [Related]
22. On the interaction of β-amyloid peptides and α7-nicotinic acetylcholine receptors in Alzheimer's disease.
Oz M; Lorke DE; Yang KH; Petroianu G
Curr Alzheimer Res; 2013 Jul; 10(6):618-30. PubMed ID: 23627750
[TBL] [Abstract][Full Text] [Related]
23. Post-transcriptional regulation of α7 nAChR expression by miR-98-5p modulates cognition and neuroinflammation in an animal model of Alzheimer's disease.
Song C; Shi J; Xu J; Zhao L; Zhang Y; Huang W; Qiu Y; Zhang R; Chen H; Wang H
FASEB J; 2021 Jun; 35(6):e21658. PubMed ID: 34010470
[TBL] [Abstract][Full Text] [Related]
24. Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice.
Sadigh-Eteghad S; Talebi M; Mahmoudi J; Babri S; Shanehbandi D
Neuroscience; 2015 Jul; 298():81-93. PubMed ID: 25881725
[TBL] [Abstract][Full Text] [Related]
25. Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists.
Kroker KS; Moreth J; Kussmaul L; Rast G; Rosenbrock H
Brain Res Bull; 2013 Jul; 96():28-38. PubMed ID: 23639920
[TBL] [Abstract][Full Text] [Related]
26. Tropisetron and its targets in Alzheimer's disease.
Hashimoto K
Expert Opin Ther Targets; 2015 Jan; 19(1):1-5. PubMed ID: 25399811
[TBL] [Abstract][Full Text] [Related]
27. Implications of Oligomeric Amyloid-Beta (oAβ
George AA; Vieira JM; Xavier-Jackson C; Gee MT; Cirrito JR; Bimonte-Nelson HA; Picciotto MR; Lukas RJ; Whiteaker P
J Neurosci; 2021 Jan; 41(3):555-575. PubMed ID: 33239400
[TBL] [Abstract][Full Text] [Related]
28. α7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles.
Medeiros R; Castello NA; Cheng D; Kitazawa M; Baglietto-Vargas D; Green KN; Esbenshade TA; Bitner RS; Decker MW; LaFerla FM
Am J Pathol; 2014 Feb; 184(2):520-9. PubMed ID: 24269557
[TBL] [Abstract][Full Text] [Related]
29. High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study.
Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Kosaka J; Kudo T; Iida H; Kishimoto T; Nagatsuka K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):920-8. PubMed ID: 26766490
[TBL] [Abstract][Full Text] [Related]
30. Beyond acetylcholinesterase inhibitors for treating Alzheimer's disease: α7-nAChR agonists in human clinical trials.
Russo P; Del Bufalo A; Frustaci A; Fini M; Cesario A
Curr Pharm Des; 2014; 20(38):6014-21. PubMed ID: 24641224
[TBL] [Abstract][Full Text] [Related]
31. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
32. Alpha7 nicotinic acetylcholine receptor expression in Alzheimer's disease: receptor densities in brain regions of the APP(SWE) mouse model and in human peripheral blood lymphocytes.
Jones IW; Westmacott A; Chan E; Jones RW; Dineley K; O'Neill MJ; Wonnacott S
J Mol Neurosci; 2006; 30(1-2):83-4. PubMed ID: 17192639
[TBL] [Abstract][Full Text] [Related]
33. A novel nicotinic mechanism underlies β-amyloid-induced neurotoxicity.
Liu Q; Xie X; Emadi S; Sierks MR; Wu J
Neuropharmacology; 2015 Oct; 97():457-63. PubMed ID: 25959067
[TBL] [Abstract][Full Text] [Related]
34. Unbalanced Regulation of α7 nAChRs by Ly6h and NACHO Contributes to Neurotoxicity in Alzheimer's Disease.
Wu M; Liu CZ; Barrall EA; Rissman RA; Joiner WJ
J Neurosci; 2021 Oct; 41(41):8461-8474. PubMed ID: 34446574
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the Relationship Between Cognitive Impairment, Glycometabolism, and Nicotinic Acetylcholine Receptor Deficits in a Mouse Model of Alzheimer's Disease.
Matsuura Y; Ueda M; Higaki Y; Sano K; Saji H; Enomoto S
Mol Imaging Biol; 2019 Jun; 21(3):519-528. PubMed ID: 30047036
[TBL] [Abstract][Full Text] [Related]
36. Differences in Aβ brain networks in Alzheimer's disease and healthy controls.
Duan H; Jiang J; Xu J; Zhou H; Huang Z; Yu Z; Yan Z;
Brain Res; 2017 Jan; 1655():77-89. PubMed ID: 27867033
[TBL] [Abstract][Full Text] [Related]
37. Probing the putative α7 nAChR/NMDAR complex in human and murine cortex and hippocampus: Different degrees of complex formation in healthy and Alzheimer brain tissue.
Elnagar MR; Walls AB; Helal GK; Hamada FM; Thomsen MS; Jensen AA
PLoS One; 2017; 12(12):e0189513. PubMed ID: 29261717
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of 1,4-Diazobicylco[3.2.2]nonane derivatives as α7-Nicotinic acetylcholine receptor PET/CT imaging agents and agonists for Alzheimer's disease.
Wang S; Fang Y; Wang H; Gao H; Jiang G; Liu J; Xue Q; Qi Y; Cao M; Qiang B; Zhang H
Eur J Med Chem; 2018 Nov; 159():255-266. PubMed ID: 30296684
[TBL] [Abstract][Full Text] [Related]
39. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
40. The distribution of the alpha7 nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [
Coughlin JM; Du Y; Rosenthal HB; Slania S; Min Koo S; Park A; Solomon G; Vranesic M; Antonsdottir I; Speck CL; Rootes-Murdy K; Lerner A; Rowe SP; Wang Y; Lesniak WG; Minn I; Bakker A; Smith GS; Dannals RF; Kuwabara H; Horti A; Wong DF; Pomper MG
Neuroimage; 2018 Jan; 165():118-124. PubMed ID: 28993233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
